Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients with HER2- Expressing Recurrent Endometrial Cancer

Next Previous
Search
Trial Profile

A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients with HER2- Expressing Recurrent Endometrial Cancer

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BNT 323 (Primary) ; Doxorubicin; Paclitaxel
  • Indications Endometrial cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms Fern-EC-01
  • Sponsors BioNTech

Most Recent Events

  • 10 Apr 2025 Timeframe for primary endpoint changed from up to approximately 52 months to up to approximately 32 months.
  • 10 Apr 2025 Planned number of patients changed from 468 to 504.
  • 10 Apr 2025 Planned End Date changed from 1 Aug 2029 to 1 Jan 2030.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top